Evidence map›Paper›PMID 33990005›Full record

ArticleMolecular immunology2021

Tumor rejection properties of gp100

Jesus A Alonso, Angela R Smith, Brian M Baker

Open access · greenAbstract read
In one paragraph

Article in Molecular immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jesus A AlonsoDepartment of Chemistry & Biochemistry and the Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN, USA.
Angela R SmithDepartment of Chemistry & Biochemistry and the Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN, USA.
Brian M BakerDepartment of Chemistry & Biochemistry and the Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN, USA. Electronic address: brian-baker@nd.edu.
University of Notre Dame · US

Funding

Structural biophysics and molecular design in cellular immunityR35GM118166 · NIGMS · UNIVERSITY OF NOTRE DAME · PI BAKER, BRIAN M · 2016 to 2025
$4.4M
Indiana Clinical and Translational Sciences InstituteTL1TR001107 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI DENNE, SCOTT C., SHEKHAR, ANANTHA · 2013 to 2017
$2.0M
BIACORE T200 SPR FOR NOTRE DAME BIOPHYSICS INSTRUMENTATION CORE (BIC) FACILITYS10OD028553 · OD · UNIVERSITY OF NOTRE DAME · PI BAKER, BRIAN M · 2020 to 2020
$343k
NCATS NIH HHS TL1 TR001107NIGMS NIH HHS R35 GM118166NIH HHS S10 OD028553
6 · The paper itself

Abstract

Although there are exceptions and outliers, T cell functional responses generally correlate with the affinity of a TCR for a peptide/MHC complex. In one recently described outlier case, the most promising clinical candidate in a series of TCRs specific for the gp100

Indexed as

Cell Line, TumorEpitopes, T-Lymphocytegp100 Melanoma AntigenHLA-A2 AntigenHumansJurkat CellsNeoplasmsProtein BindingReceptors, Antigen, T-CellSurface Plasmon ResonanceT-LymphocytesEpitopes, T-Lymphocytegp100 Melanoma AntigenHLA-A2 AntigenReceptors, Antigen, T-CellBinding affinitygp100HeterocliticPeptideT cell receptor

Identifiers

PMID33990005
PMCPMC8184619
OpenAlexW3160247688

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.